J Yeungnam Med Sci.
2023 Jul;40(3):241-246. 10.12701/jyms.2022.00745.
Advances in management of pediatric chronic immune thrombocytopenia: a narrative review
- Affiliations
-
- 1Department of Pediatrics, Yeungnam University College of Medicine, Daegu, Korea
- KMID: 2544583
- DOI: http://doi.org/10.12701/jyms.2022.00745
Abstract
- Immune thrombocytopenia (ITP) is a disease in which thrombocytopenia occurs because of immune-mediated platelet destruction and decreased platelet production. Although many pediatric patients with ITP experience spontaneous remission or reach remission within 12 months of first-line therapy, approximately 20% progress to chronic ITP. Patients who do not respond to first-line treatment or experience frequent relapses are of great concern to physicians. This review summarizes recent treatments for second-line treatment of pediatric chronic ITP.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Diagnostic Approach of Childhood Immune Thrombocytopenia
- Recent advances in treatments of adult immune thrombocytopenia
- Diagnosis and management of thrombocytopenia in pregnancy
- Quick drop of platelet counts in children with chronic immune thrombocytopenia after COVID-19 mRNA vaccination: case reports
- IVIG Treatment Response and Age are Important for the Prognosis of Pediatric Immune Thrombocytopenia
